Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388456 | 0.98 | MEN1 (0.46) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL29467663 | 0.93 | MEN1 (0.44) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL1509845 | 0.91 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL3703562 | 0.91 | MEN1 (0.47) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL16315843 | 0.91 | MEN1 (0.47) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL20466265 | 0.91 | IDO1 (0.41) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL4394882 | 0.91 | MEN1 (0.53) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL31298558 | 0.90 | MEN1 (0.48) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL25257785 | 0.89 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL14671684 | 0.89 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| EP-2292653-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| EP-1846447-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| US-7161034-B2 | Lidocaine analogs and methods of making and using same | DADE BEHRING INC. (US) | 2007-01-09 | — | — | US | disclosed |
| WO-2006082205-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | CD2BP2, DNPEP, LNPEP | MEN1 1711/4885GAA 834/4885KMT2A 3687/4885 |
| US-20100227796-A1 | Insulin Derivatives | IAPP, INSR, GCG | MEN1 2119/4885GAA 671/4885KMT2A 4184/4885 |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BCL2, BAX, BCL2L1 | MEN1 4006/4885GAA 872/4885KMT2A 3524/4885 |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | MEN1 1711/4885GAA 834/4885KMT2A 3687/4885 |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BCL2, BAX, BCL2L1 | MEN1 4006/4885GAA 872/4885KMT2A 3524/4885 |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | MEN1 4006/4885GAA 872/4885KMT2A 3524/4885 |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | MEN1 4006/4885GAA 872/4885KMT2A 3524/4885 |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | MEN1 2390/4885GAA 1395/4885KMT2A 4091/4885 |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | MEN1 3369/4885GAA 263/4885KMT2A 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.